* Says human neural stem cells promising in animal studies
* Says plans to start clinical studies in 2011
* Shares up 37 pct
Aug 19 StemCells Inc (STEM.O) said its
proprietary human neural stem cells restored motor functions in
mice being treated for chronic spinal injuries, sending shares
of the biotechnology company up as much as 37 percent.
In the animal study, human neural stem cells were
administered to mice after the end of acute trauma -- a chronic
phase that typically goes on for several weeks or months
following injury in humans.
"These exciting results demonstrate an expanded window of
opportunity for human neural stem cell intervention in spinal
cord injury," the company's Head of Central Nervous System
Program Stephen Huhn said.
The Palo Alto, California-based company plans to start
human trials on the product in 2011. StemCells shares, which
had jumped about 8 percent when it said human neural stem cell
improved vision in animal studies in mid-October last year,
were up about 20 percent at $1.04 Thursday morning, on Nasdaq.
They touched a high of $1.19 earlier in the session.
(Reporting by Vidya L Nathan, Rajarshi Basu in Bangalore;
Editing by Jarshad Kakkrakandy)